<DOC>
	<DOC>NCT02035215</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia</brief_summary>
	<brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>LDL≥160mg/dl, 200mg/dl≤TG&lt;500mg/dl In the case of smokers, he agrees should be smokefree In the case of women of childbearing age, urine pregnancy test must be negative Patients with acute artery disease within 3 months History of revascularization procedure or aneurism operation within 6months Patients with myopathy, rhabdomyolysis Patients with pancreatitis Patients with HIV positive History of malignant tumor within 2 years Patients must be treated with medications prohibited for concomitant use during study period Patients with uncontrolled hypertension(SBP&gt;180mmHg or DBP&gt;110mmHg) Serum Creatinine&gt;1.2mg/dl(female), &gt;1.4mg/dl(male) AST or ALT &gt; 2X ULN CPK &gt; 2X ULN Patients with galactose intolerance or Lapp lactase deficiency, glucosegalactose malabsorption Allergy or Hypersensitive to investigational drug History of drug or alcohol abuse within 2 years In the case of smokers, who do not intend to non smoking Women with pregnant, breastfeeding Patients treated with any investigational drugs within 1 month at the time consents are obtained Not eligible to participate for the study at the discretion of investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hyperlipidemia, Familial Combined</keyword>
	<keyword>Omega 3 acids ethylesters 90</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>